Dymon Asia Capital (Singapore)’s Revolution Medicines RVMD Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.22M	Buy	+6,500	New	+$949K	0.05%	155

Other funds holding RVMD

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s RVMD Position: Q2 2026 in Review

Dymon Asia Capital (Singapore) opened a new position in Revolution Medicines (RVMD) in Q2 2026: 6,500 shares worth $1.22M. The stake represents 0.05% of the portfolio and ranks #155 among its holdings.

208 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Dymon Asia Capital (Singapore) held 6,500 shares of Revolution Medicines worth $1.22M as of Q2 2026.
Revolution Medicines was a new Dymon Asia Capital (Singapore) position in Q2 2026.
Revolution Medicines made up 0.05% of Dymon Asia Capital (Singapore)'s portfolio in Q2 2026, its #155 holding.
208 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q2 2026, filed 23 Jul 2026.